Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The body weight-based thrombolytic medication strategy in clinical trials shows critical defects in recanalization rate and post-thrombolysis hemorrhage. Methods for perceiving thrombi heterogeneity of thrombolysis resistance is urgently needed for precise thrombolysis. Here, we revealed the relationship between the thrombin heterogeneity and the thrombolysis resistance in thrombi and created an artificial biomarker-based nano-patrol system with robotic functional logic to perceive and report the thrombolysis resistance of thrombi. The nano-patrols are contrallable and are able to accomplish thrombolysis resistance-matched personalized and precise therapy according to the feedback signal from artificial biomarkers. This nano-patrol system depicted more enhanced thrombolytic efficiency (elevated by 25%) than alteplase for mini pig model and clinical thrombi and achieved recanalization in thrombotic model where alteplase encountered failure. Moreover, the nano-patrol remarkably reduced the infarct volume and the hemorrhagic transformation risk (0.12-fold of alteplase) of cerebral thrombosis. Therefore, we developed a unique tool for diagnosing thrombolysis resistance and achieving personalized and precise thrombolysis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740970 | PMC |
| http://dx.doi.org/10.1126/sciadv.adr0377 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Effect of Remote Ischemic Conditioning in Patients Treated with Endovascular Therapy: A RESIST Trial Post Hoc Study.
Transl Stroke Res
September 2025
Department of Neurology, Aarhus University Hospital, Palle Juul Jensens Boulevard 165, Entrance J 518, 8200, Aarhus N, Aarhus, Denmark.
Remote ischemic conditioning (RIC) is a simple, non-invasive procedure that has been shown to be safe and feasible in multiple smaller clinical trials. Recent large randomized controlled trials have yielded mixed results regarding clinical effect. Patients with severe stroke may experience greater benefit from cerebroprotective interventions, highlighting the need for adjunctive therapies to enhance endovascular therapy (EVT) outcomes.
View Article and Find Full Text PDFPredictors of early resistance to catheter-directed thrombolysis in patients with proximal deep vein thrombosis.
Eur J Radiol
August 2025
Department of Interventional and Vascular Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, PR China. Electronic address:
Purpose: To determine predictors of immediate thrombolysis resistance (iTR) in patients with proximal deep vein thrombosis (DVT), defined as thrombosis involving the femoral or more proximal veins, with or without concomitant popliteal vein involvement, and to investigate its impact on long-term post-thrombotic syndrome (PTS) outcomes.
Methods: This single-center retrospective study reviewed consecutive patients who underwent catheter-directed thrombolysis (CDT) as first-line therapy. Baseline demographics, clinical history, comorbidities and provoking risk factors for DVT, intraprocedural findings, periprocedural complications, and follow-up outcomes were compared between the iTR and immediate thrombolysis success (iTS) groups.
N-acetylcysteine (NAC) as an adjunct to intravenous fibrinolysis in patients with acute ischemic stroke: a single group study (NAC-Safety).
Neuroscience
August 2025
Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institut Blood and Brain @ Caen-Normandie (BB@C), 14000 Caen, France; Department of Neurology, Caen-Normandie University Hospital, CHU, Caen, France.
Recombinant tissue plasminogen activator (alteplase) and its derivative tenecteplase are approved for acute ischemic stroke (AIS), but their low recanalization rates remain a limitation. Resistance to intravenous (IV) fibrinolysis may arise from platelet cross-linking during arterial thrombosis, mediated by von Willebrand factor (VWF) multimers. N-Acetylcysteine (NAC) has demonstrated potential to cleave large VWF multimers in preclinical studies, suggesting its potential as an adjunct therapy.
View Article and Find Full Text PDFSuccessful Treatment of Acute Bilateral Pulmonary Thromboembolism Using Accelerated Regimen of Thrombolytics: A Case Report.
Cureus
July 2025
Cardiology Unit, National Hospital of Sri Lanka, Colombo, LKA.
Acute pulmonary thromboembolism represents a critical, life-threatening condition that necessitates immediate and effective management to minimize associated mortality. Although the current recommendation for managing hemodynamically unstable pulmonary embolism (PE) is the regimen of 100 mg recombinant tissue plasminogen activator (rtPA) administered over two hours, an accelerated regimen of rtPA (0.6 mg/kg over 15 minutes, maximum 50 mg) has also been described for the management of PE and circulatory arrest.
View Article and Find Full Text PDFFatty acid albumin conjugates mechanically weaken and disrupt degradation of fibrin networks.
Acta Biomater
August 2025
Department of Biomedical Engineering, University of Texas at Austin, Austin, TX 78712, USA. Electronic address:
Cardiovascular diseases and stroke together account for the largest causes of death in Western countries. These pathologies are directly linked to the formation of blood clots that block blood flow to vital organs. Common risk factors for such clots are obesity, high blood pressure, diabetes, and high LDL cholesterol.
View Article and Find Full Text PDF